Chronic hepatitis B (CHB) is a serious liver disease worldwide，HBV MTCT is the important
reason to keep high prevalence of chronic HBV infection in China. Intrapartum infection is
the main period of neonatal HBV infection. Injecting HBIG and hepatitis b vaccine immediately
after birth is the most important method of blocking mother-to-child transmission of HBV.
However, regular doses of HBIG combined with hepatitis b vaccine blocking measures still have
a failure rate as high as 5% ~ 15%.There are numerous studies to explore pregnancy women with
HBV positive, especially high viral load of those women during pregnancy being treated with
nucleoside analogs to increase the blocking rate of HBV MTCT, but there is still a failure
rate of 2.2% to 18%. In this study, we will explore the efficiency of personalized blocking
method of HBV maternal-neonatal transmission in high-risk newborns,according to the venous
blood HBsAg state of neonatus at birth.